Antares Pharma to Report First Quarter 2019 Financial and Operating Results
April 18 2019 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release
its first quarter 2019 financial results and recent operating
progress before the market opens on Thursday, May 2, 2019.
Management will host a webcast and conference call at 8:30 a.m. ET
(Eastern Time) on May 2, 2019 to discuss the results.
Interested parties may participate in the
conference call by dialing 1-800-458-4121 or 1-323-794-2597 and
entering access code 2251670. We encourage interested parties
to dial into the conference call at least 10 minutes prior to the
scheduled start time. A replay of the conference call will be
available from 11:30 a.m. ET on Thursday, May 2, 2019, through
11:30 a.m. ET on Saturday, June 1, 2019 by dialing 1-888-203-1112
or 1-719-457-0820 and entering the access code 2251670. An
archive of the slide presentation will also be available under the
“For Investors” section of the Antares Website at
www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused on the development and commercialization of
self-administered parenteral pharmaceutical products using advanced
drug delivery auto injector technology. The Company has a
portfolio of proprietary and partnered commercial products with
several product candidates in advanced stages of development, as
well as significant strategic alliances with industry leading
pharmaceutical companies including Teva Pharmaceutical Industries,
Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc.
(Pfizer). Antares Pharma’s proprietary products include
XYOSTED™ (testosterone enanthate) injection, OTREXUP®
(methotrexate) injection for subcutaneous use and Sumatriptan
Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995 This
press release contains forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors
that may cause such differences include, but are not limited to:
the timing and results of the clinical development program with
orphan designation to evaluate the use of subcutaneous methotrexate
for the treatment of ectopic pregnancy that meets predefined
criteria for medical management; the ability to
maintain orphan drug designation, receive ultimate product
approval, and receive the advantages of orphan drug designation;
market acceptance, adequate reimbursement coverage and commercial
success of XYOSTED™ and future revenue from the same; market
acceptance of Teva’s generic epinephrine auto-injector product and
future revenue from the same; successful completion of the
transaction with Ferring International Center, S.A.; future market
acceptance and revenue from Makena® subcutaneous auto injector;
Teva’s ability to successfully commercialize VIBEX® Sumatriptan
Injection USP and the amount of revenue from the same; continued
growth of prescriptions and sales of OTREXUP®; the timing and
results of the Company’s or its partners’ research projects or
clinical trials of product candidates in development including
projects with Teva and Pfizer; actions by the FDA or other
regulatory agencies with respect to the Company’s products or
product candidates of its partners; continued growth in product,
development, licensing and royalty revenue; achievement of the 2019
revenue guidance; the Company’s ability to obtain financial and
other resources for its research, development, clinical, and
commercial activities and other statements regarding matters that
are not historical facts, and involve predictions. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance, achievements or
prospects to be materially different from any future results,
performance, achievements or prospects expressed in or implied by
such forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Jul 2023 to Jul 2024